Cowen, Deutsche Bank assisted; deal funds general corporate purposes
By Devika Patel
Knoxville, Tenn., July 2 - Omeros Corp. said it settled a $34.5 million public offering of stock. The deal was announced June 26 and priced for $30 million with a 15% greenshoe on June 27.
The company sold 3,365,854 common shares at $10.25 apiece. Of the shares, 439,024 were part of the fully exercised greenshoe. The price per share is a 22.64% discount to the June 26 closing share price of $13.25.
Cowen and Co. and Deutsche Bank Securities were the joint bookrunning managers. Canaccord Genuity Inc. and Wedbush PacGrow Life Sciences were the co-managers.
Proceeds will be used for general corporate purposes, including the clinical development of OMS302 and OMS103HP, research and development, preclinical studies and clinical trials, capital expenditures, working capital and advancing product candidates towards commercialization.
Omeros is a biopharmaceutical company based in Seattle.
| Issuer: | Omeros Corp.
|
| Issue: | Common shares
|
| Amount: | $34.5 million (including $4.5 million greenshoe exercise)
|
| Shares: | 3,365,854
|
| Price: | $10.25
|
| Warrants: | No
|
| Bookrunners: | Cowen and Co. and Deutsche Bank Securities
|
| Announcement date: | June 26
|
| Pricing date: | June 27
|
| Settlement date: | July 2
|
| Stock symbol: | Nasdaq: OMER
|
| Stock price: | $13.25 at close June 26
|
| Market capitalization: | $229.67 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
